TNF-α (etanercept, infliximab, golimumab, adalimumab, certolizumab pegol), IL-1 (anakinra, canakinumab, gevokizumab) and IL-6 inhibitors (tocilizumab, sarilumab, olokizumab) are biological drugs available on the pharmaceutical market for the treatment of RA. This evidence concerns the gene IL6 and rheumatoid arthritis.